Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer

Pharmacogenetics and Genomics

Volumn 25, Issue 1, 2015, Pages 30-37

  Sebio, Ana ^a   Gerger, Armin ^a,b   Matsusaka, Satoshi ^a   Yang, Dongyun ^a   Zhang, Wu ^a   Stremitzer, Stefan ^a   Stintzing, Sebastian ^a   Sunakawa, Yu ^a   Yamauchi, Shinichi ^a   Ning, Yan ^a   Fujimoto, Yoshiya ^c   Ueno, Masashi ^c   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Adjuvant; Colon cancer; Obesity; Polymorphisms; Recurrence

Indexed keywords

BIOLOGICAL MARKER; CD36 ANTIGEN; DEVELOPMENTALLY REGULATED GTP BINDING PROTEIN 1; DOWN SYNDROME CRITICAL REGION 1 GENE PROTEIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LEPTIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OXALIPLATIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REGENERATING GENE IA PROTEIN; UNCLASSIFIED DRUG; MUSCLE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RCAN1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; AGED; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COLON CANCER; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; OBESITY; OVERALL SURVIVAL; PROBABILITY; PROCEDURES; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR LOCALIZATION; TUMOR RECURRENCE; ASIAN CONTINENTAL ANCESTRY GROUP; COLON TUMOR; GENETIC ASSOCIATION STUDY; GENETICS; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COLONIC NEOPLASMS; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MUSCLE PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR ALPHA; PROGNOSIS;

EID: 84918543840     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000101     Document Type: Article

References (43)

1. Edge S, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
2. Poplin EA, Benedetti JK, Estes NC, Haller DG, Mayer RJ, Goldberg RM, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005; 23:1819-1825.
3. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27:3109-3116.
4. Adams KF, Leitzmann MF, Albanes D, Kipnis V, Mouw T, Hollenbeck A, Schatzkin A. Body mass and colorectal cancer risk in the NIH-AARP cohort. Am J Epidemiol 2007; 166:36-45.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625-1638.
6. Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O'Connell MJ, Wolmark N. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst 2006; 98:1647-1654.
7. Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel AV, Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2012; 30:42-52.
8. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB 3rd, Macdonald JS, Fuchs CS. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer 2003; 98:484-495.
9. Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, et al. Cancer and Leukemia Group B 89803. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 2008; 26:4109-4115.
10. Gao J, Tian J, Lv Y, Shi F, Kong F, Shi H, Zhao L. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci 2009; 100:389-395.
11. Dong Z, Fu S, Xu X, Yang Y, Du L, Li W, et al. Leptin-mediated regulation of ICAM-1 is Rho/ROCK dependent and enhances gastric cancer cell migration. Br J Cancer 2014; 110:1801-1810.
12. Jaffe T, Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int J Cancer 2008; 123:2543-2556.
13. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140:197-208.
14. Vaiopoulos AG, Athanasoula KCh, Papavassiliou AG. NF-κB in colorectal cancer. J Mol Med (Berl) 2013; 91:1029-1037.
15. Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, Kim TS. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. J Biol Chem 2000; 275:32681-32687.
16. Cortez M, Carmo LS, Rogero MM, Borelli P, Fock RA. A high-fat diet increases IL-1, IL-6, and TNF-α production by increasing NF-κB and attenuating PPAR-γ expression in bone marrow mesenchymal stem cells. Inflammation 2013; 36:379-386.
17. Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 2000; 60:749-755.
18. Rechreche H, Montalto G, Mallo GV, Vasseur S, Marasa L, Soubeyran P, et al. pap, reg Ialpha and reg Ibeta mRNAs are concomitantly up-regulated during human colorectal carcinogenesis. Int J Cancer 1999; 81:688-694.
19. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996; 38:414-420.
20. Bush CR, Havens JM, Necela BM, Su W, Chen L, Yanagisawa M, et al. Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor gamma and calcium signaling in human colorectal cancer cells. J Biol Chem 2007; 282:23387-23401.
21. Riemann K, Becker L, Struwe H, Rübben H, Eisenhardt A, Siffert W. Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther 2007; 45:423-430.
22. Hoffstedt J, Eriksson P, Mottagui-Tabar S, Arner P. A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. Horm Metab Res 2002; 34: 355-359.
23. Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20:284-287.
24. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, et al. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 1998; 7:435-440.
25. Ondrey F. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention. Clin Cancer Res 2009; 15:2-8.
26. Kato M, Kusumi T, Tsuchida S, Tanaka M, Sasaki M, Kudo H. Induction of differentiation and peroxisome proliferator-activated receptor gamma expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 2004; 130:73-79.
27. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 2001; 11:764-768.
28. Shao J, Sheng H, DuBois RN. Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2002; 62:3282-3288.
29. Sharma C, Pradeep A, Wong L, Rana A, Rana B. Peroxisome proliferatoractivated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem 2004; 279:35583-35594.
30. Chen J, Iverson D. Estrogen in obesity-associated colon cancer: friend or foe? Protecting postmenopausal women but promoting late-stage colon cancer. Cancer Causes Control 2012; 23:1767-1773.
31. Barzi A, Lenz AM, Labonte MJ, Lenz HJ. Molecular pathways: estrogen pathway in colorectal cancer. Clin Cancer Res 2013; 19:5842-5848.
32. Xu W, Li Y, Wang X, Chen B, Liu S, Wang Y, et al. PPARgamma polymorphisms and cancer risk: a meta-analysis involving 32 138 subjects. Oncol Rep 2010; 24:579-585.
33. Fuentes JJ, Genescà L, Kingsbury TJ, Cunningham KW, Pérez-Riba M, Estivill X, de la Luna S. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways. Hum Mol Genet 2000; 9:1681-1690.
34. Fürstenau U, Schwaninger M, Blume R, Jendrusch EM, Knepel W. Characterization of a novel calcium response element in the glucagon gene. J Biol Chem 1999; 274:5851-5860.
35. Harris CD, Ermak G, Davies KJ. Multiple roles of the DSCR1 (Adapt78 or RCAN1) gene and its protein product calcipressin 1 (or RCAN1) in disease. Cell Mol Life Sci 2005; 62:2477-2486.
36. Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002; 359:1019-1025.
37. Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 2009; 459:1126-1130.
38. Yao YG, Duh EJ. VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis? Biochem Biophys Res Commun 2004; 321:648-656.
39. Bauer KM, Hummon AB, Buechler S. Right-side and left-side colon cancer follow different pathways to relapse. Mol Carcinog 2012; 51:411-421.
40. Zhu H, Wu TC, Chen WQ, Zhou LJ, Wu Y, Zeng L, Pei HP. Screening for differentially expressed genes between left- and right-sided colon carcinoma by microarray analysis. Oncol Lett 2013; 6:353-358.
41. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, et al. VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 2008; 28 (6B):3865-3870.
42. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 2012; 22:1790-1797.
43. Badis G, Berger MF, Philippakis AA, Talukder S, Gehrke AR, Jaeger SA, et al. Diversity and complexity in DNA recognition by transcription factors. Science 2009; 324:1720-1723.